AI Article Synopsis
- High-risk serotypes of human papillomavirus (hr-HPV) are strongly linked to cervical cancer, making hp-HPV testing essential for effective screening.
- hr-HPV testing is increasingly used alongside cervical cytology to enhance sensitivity and is also considered as a primary testing method.
- Triage strategies for hr-HPV-positive women include HPV genotyping, p16/Ki-67 dual staining, and methylation assays, each with their own advantages and limitations.
Article Abstract
Background: The association between high-risk serotypes of human papillomavirus (hr-HPV) and cervical cancer is well-established.
Summary: In order to improve the sensitivity of cervical cytology testing, hr-HPV testing has rapidly become part of routine cervical cancer screening, either in conjunction with cytology or as primary testing. In this review, we discuss the overall utility and strategies of hr-HPV testing, as well as the advantages and limitations of potential triage strategies for hr-HPV-positive women, including HPV genotyping, p16/Ki-67 dual staining, and methylation assays.
Key Message: hr-HPV testing is discussed as primary screening and HPV genotyping, p16/Ki-67 dual staining, and methylation assays are discussed as ancillary techniques to cytology in the triage of hr-HPV-positive women undergoing cervical cancer screening.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000528931 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!